Quantifying the Costs of Serious Adverse Drug Reactions to Antiepileptic Drugs
|
|
- Kevin Cobb
- 5 years ago
- Views:
Transcription
1 Epiiepsia, 39(Suppl. 7):S27-S32, 1998 Lippincott Williams & Wilkins, Philadelphia 0 International League Against Epilepsy Quantifying the Costs of Serious Adverse Drug Reactions to Antiepileptic Drugs *Raymond G. Schlienger, *Paul I. Oh, *Sandra R. Knowles, and *?Neil H. Shear Divisions of Clinical Pharmacology and fdermatology, Department of Medicine and Pharmacology, Sunnybrook Health Science Centre, University of Toronto, Toronto, Ontario, Canada Summary: Purpose: We assessed from an institutional perspective the direct costs of severe adverse cutaneous or hypersensitivity reactions due to antiepileptic drug (AED) therapy that led to hospitalization or prolonged hospital stay. Methods: Patients admitted for or developing severe AEDinduced cutaneous or hypersensitivity reactions while in hospital from January 1990 through June 1996 were identified by ICD-9 codes E936, E937, E693, E695.1, E995.1, and E Identified cases were analyzed retrospectively by chart review and were included in the analysis if a causal relationship was determined to be possible, probable, or definite. Clinical outcomes were abstracted and related direct costs of the adverse drug reactions ( ADRs) calculated. Results: A total of 384 cases were identified by ICD-9 codes, of which 13 cases (mean age f SD 52.9 f 21.0 years) were included for further analysis. Eight patients (62%) were admitted because of an ADR (median length of stay 9.5 days; range 4-43), five (38%) experienced an ADR during hospitalization (median duration of ADR episodes 8.5 days; range: 7-21 days). The median direct medical costs of the ADRs were Canadian (CDN) $3,128 (range 1,149-21,293) per patient. Conclusions: The management of serious cutaneous and hypersensitivity ADRs due to AEDs is associated with considerable direct medical costs. These figures should be considered along with drug acquisition costs and treatment of clinical successes and failures in the overall assessment of the economic impact of pharmacotherapy. Prospective collection of direct costs associated with ADRs in clinical trials would be of value. Key Words: Antiepileptic drugs-adverse drug reactions- Skin-Hypersensitivity-Costs. To accurately reflect the total management costs, pharmacoeconomic analyses should include the evaluation of costs related to negative outcomes of pharmacotherapy such as adverse drug reactions (ADRs). Like any type of illness, ADRs may require treatment ranging from minor symptomatic care to very expensive, intensive hospitalization or support for the victim for the rest of his or her life (1). In addition to direct medical costs attributable to an ADR (e.g., costs for diagnosis and treatment, physician fees, hospitalization), potential disability, loss of employment, or death are all associated with significant additional indirect, nonmedical costs. The antiepileptic drugs (AEDs) phenytoin (PHT), carbamazepine (CBZ), phenobarbital (PB), and valproate (VPA) are effective for the treatment of partial and generalized tonic-clonic seizures (2). CBZ and VPA are also effective in the management of psychiatric diseases such as bipolar disorders (3,4). However, the therapeutic benefit of these AEDs may be limited by potentially severe Address correspondence and reprint requests to Dr. N. H. Shear at Division of Clinical Pharmacology, Room E-240, Sunnybrook Health Science Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5. ADRs. The most common ADRs involve the central n&rvous system (e.g., somnolence, nystagmus, ataxia) and the skin (most often exanthematous rashes) (5,6). More severe drug-induced skin reactions, such as erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), may also develop (5). Such severe cutaneous reactions to AEDs are rare, occurring in less than 1% of patients treated (5,7-9). It has been estimated that one in 450 adult patients treated with CBZ requires admission to the hospital because of a cutaneous reaction (lo). A rash may also be a marker of a severe systemic reaction, the AED hypersensitivity syndrome (AHS), which is characterized by the triad of fever, skin rash, and single or multiorgan system involvement (e.g., hepatitis, blood dyscrasias, nephritis) (1 1). In a recent cohort study, the risk for this syndrome in first-time users of PHT or CBZ was estimated at /10,000 and 1-4.1/10,000 patients, respectively (12). However, up to 3 1 % of patients receiving AED therapy may complain of one or more ADRs, as shown in a recent multicenter survey. More than half of these reactions were considered to be clinically significant, and hospital admission S2 7
2 S28 R. G. SCHLIENGER ET AL. was required in 8.3% of the patients with an AEDassociated ADR (6). Newer AEDs such as gabapentin (GBP), lamotrigine (LTG), vigabatrin (VGB), and felbamate (FBM) have been approved as add-on drugs in adults with partial seizures or secondarily generalized seizures ( 13,14). However, as with the older agents, severe ADRs, such as SJS or TEN with LTG or aplastic anemia and fatal liver reactions with FBM, have been reported (14). In a recent cost-minimization analysis from the United Kingdom comparing VGB, LTG, and GBP as add-on therapy in patients with partial seizures, ADRs were estimated to be responsible for % of the total direct costs of treatment in the first year of use (15). Studies determining the direct economic consequences associated with severe cutaneous or hypersensitivity reactions due to AEDs are lacking. In this study we evaluated the clinical outcomes of these reactions and their related direct costs from a hospital perspective. METHODS Sunnybrook Health Science Centre (SHSC) is a 1,300- bed teaching hospital, affiliated with the University of Toronto, Ontario, Canada, which provides primary and tertiary care. It serves a catchment area with an estimated population of approximately 235,OQO. At the time of our study the hospital had no burn unit and did not serve as a specific referral center for patients with SJS or TEN. Patients hospitalized from January 1990 through June 1996 with an ADR potentially associated with AED therapy, and patients who experienced such a reaction during their hospital stay, were identified by a medical records database search using ICD-9 codes E936 and E937 [drugs, medicinal and biologic substances causing adverse effects in therapeutic use including AEDs and anti-parkinson drugs (E936) and sedatives and hypnotics (E937)] (16). To increase the number of potential cases, we also reviewed the hospital records for the ICD-9 codes E693 (dermatitis due to drugs), E695.1 (erythema multiforme, SJS, TEN), E995.1 (ADR unspecified), and E995.2 (allergy unspecified). Charts of patients identified by these codes were analyzed retrospectively. Patients were included who were identified as having been hospitalized for an AEDinduced cutaneous or hypersensitivity reaction in whom the causal relationship was assessed as either definite, probable, or possible. Patients identified as having an AED-induced reaction during their hospital stay were included if the ADR was classified either as a severe cutaneous reaction (defined as EM, SJS, or TEN) or as an AHS reaction (defined as rash with fever and single or multiple organ involvement), or if they experienced any cutaneous or hypersensitivity reaction leading to an estimated prolongation of their hospital stay of at least 3 days. The causal relationship had to be assessed as either definite, probable, or possible. Causality assessment was performed using a validated 10-item rating system for ADRs (17). The clinical details of the cases were abstracted (demographics, seizure history, associated conditions, drug exposure, details and time course of reaction) along with specific items representing hospital resource utilization (drugs, physician visits, laboratory tests, radiology). Costing of the entire admission was achieved through the hospital accounting system (Transition Systems Incorporated) with a breakdown of costs by department [nursing (including costs for nursing, hospital bed, and overhead costs), laboratory, and pharmacy (including drug costs and pharmacy operational costs)]. For patients admitted for an AED-induced ADR, the costs for the event were equated with the costs for their entire hospital stay. For patients who experienced an AED-induced ADR during hospitalization for another condition (e.g., neurosurgery for brain tumor), the costs associated with the reaction were derived as the proportion of the hospitalization attributable to the ADR over the total length of stay. Costs for nursing were estimated by dividing the total costs for nursing by the ratio between the length of the hospital stay and the length of the ADR episode. Costs for physicians (including specialist consultations and physician costs for patients with follow-up visits as outpatients), costs for laboratory tests, drugs, noninvasive and invasive procedures for the duration of the ADR were abstracted from the patient charts and from the accounting system. Costs were estimated in Canadian Dollars (CDN 8). Measures to adjust for inflation during the study period were not taken into account. Descriptive statistics were used to analyze the data. RESULTS A total of 384 cases with either a single or a combination of several of the ICD-9 codes E936 or E937 (12.5%), E693 (46.6%). E695.1 (5.5%). E995.1 or E995.2 (24.2%), or a combination of E936/937 with one of the other codes ( 11.2%), were identified. In 82 cases (21%) the reaction was potentially associated with the use of an AED. Of these, 69 cases were excluded for the following reasons: no increase in the length of stay in patients who developed the reaction during hospitalization (48%); the reported ADR was neither a cutaneous nor a hypersensitivity reaction (46%); and no causal relationship with the AED (6%). We were therefore left with a sample of 13 cases with AED-associated severe cutaneous or hypersensitivity ADRs, highlighting the fact that these severe events occur infrequently. The mean age (+SD) of these patients was 52.9 years (+21.0 years); 62% were females. Eight patients (62%) were
3 COSTS OF ADVERSE REACTIONS TO AEDS S29 hospitalized because of an AED-induced ADR; five (38%) experienced an AED-induced ADR during their hospital stay. None of the reactions was fatal. In seven patients the reaction was associated with PHT, in three with VPA, in two with CBZ, and in one with combined PHT and CBZ (Table 1). Nine patients were receiving long-term therapy with AEDs (two for bipolar disorders, seven for seizure disorders); four patients received shortterm prophylactic therapy. On average, ADR diagnosis and treatment provoked 54.4 laboratory tests (e.g., electrolytes, liver function tests, uredcreatinine), 1.7 specialist consultations, 0.5 noninvasive procedures (x-ray, CT scan), 0.2 invasive procedures (skin biopsy), and 3.7 drug treatments (number of drugs and different dosage forms of the same therapeutic class used for the treatment of the ADR) per case. The calculated total costs that resulted from AED-induced severe cutaneous or hypersensitivity ADRs during the study period of 78 months was CDN $71,518, of which CDN $44,426 (62%) was attributable to ADRs leading to hospitalization and CDN $27,092 (38%) to reactions that occurred during hospitalization. Hence, the mean costs for AEDinduced severe reactions at our institution during the study period were CDN $11,003 per year. The median length of stay for patients admitted for an ADR was 9.5 days. The median duration of ADR episodes in patients who experienced a reaction during hospitalization was 8.5 days. The median direct medical cost for severe cutaneous and hypersensitivity reactions to AEDs was CDN $3,128 (Table 2). The most important cost-driving component was the costs associated with nursing (including room charges and overhead costs), which were responsible for almost two-thirds of the total costs. A more detailed breakdown of costs is presented in Table 3. DISCUSSION In two recent United States studies from 1993 and 1995, the direct costs of medication-related problems, such as ADRs and medication errors, at two universityaffiliated hospitals were estimated to be almost U.S. $1.1 million and U.S. $1.5 million per year, respectively (18,19). In another recent United States study in a 520- bed teaching hospital, the additional hospital costs for patients with ADRs during hospitalization were estimated to be almost U.S. $3.2 million during the study period of 4 years (20). In the present study the total direct costs for severe cutaneous or hypersensitivity reactions caused by AEDs at our institution averaged CDN $11,003 (=US. $8,032) per year. This is a relatively small figure compared to the aforementioned studies, but we calculated only the costs related to severe ADRs of one specific therapeutic group, whereas in all of the above-mentioned evaluations the objective was to calculate the total costs associated with ADRs in general. We equated the direct medical costs for patients admitted because of an ADR with the costs for their entire hospital stay. In some of these patients this might have led to a overestimation of the costs related to the ADR because of costs associated with concurrent diseases and their drug therapies. However, because nursing and laboratory costs directly associated with the ADRs were the main cost factors, additional costs induced by therapies for other co-morbidities were regarded as minor. Calculation of costs for patients who experience a reaction during hospitalization is more difficult to estimate. It is often hard to assess if and how much a reaction really contributed to additional hospital days, especially when the underlying disease is severe. Therefore, our approach TABLE 1. Characteristics of 13 patients hospitalized or with prolonged hospital stay due to severe cutaneous or hypersensitivity ADRs induced by AEDs Patient Age Sex Indication for AED AED ADR 1" 28 F Prophylaxis after neurosurgery Phenytoin AHS (rash, fever, facial edema, lymphadenopathy, hepatitis, increased WBC) 2" F F Prophylaxis after neurosurgery Bipolar disorder Carbamazepine Valproate AHS (erythema, fever, generalized lymphadenopathy, facial edema, anemia) AHS (exanthematous rash, fever, cholestatic hepatitis, facial edema) 4 20 F Bipolar disorder Valproate Cholestatic hepatitis 5" 72 M Prophylaxis due to brain metastases Phenytoin EM 6" 59 M Prophylaxis due to brain metastases Carbamazepine Generalized rash 7" 67 F Generalized seizures Phenytoin Rash, fever, lethargy 8" 78 M Seizures secondary to stroke Valproate Rash 9 65 M Prophylaxis after neurosurgery Phenytoin AHS (rash, fever, increased AST) 10" 69 F Idiopathic seizure disorder Phenytoidcarbamazepine Hepatitis F Postoperative seizures Phenytoin Rash 12" 46 M Seizures secondary to brain metastases Phenytoin SJS M Seizures secondary to CNS lymphoma Phenytoin Rash LI Hospitalized because of AED-induced ADR. AHS, antiepileptic drug hypersensitivity syndrome; ADR, adverse drug reaction: AST, aspartate aminotransferase: EM, erythema multiforme; SJS, Stevens-Johnson syndrome; WBC, white blood cell count: AED, antiepileptic drug. Epilepsia, Vol. 39, Suppl. 7, 1998
4 S30 R. G. SCHLIENGER ET AL. TABLE 2. Length of stay, length of ADR episode during hospitalization, and total direct costs for patients admitted for an AED-induced ADR and patients who experienced an ADR during hospitalization ADRs leading to ADRs during hospitalization hospitalization All ADRs (n = 8) (n = 5) (n = 13) LOS (days) Mean f SD f Median Range Duration of ADR episode during hospitalization (days) Mean f SD 14.6 r f f 10.7 Median Range Total direct costs (CDN$)" Mean f SD 5,553 f 6,638 5,419 f 4,147 5, ,607 Median 2,780 3,806 3,128 Range 1, , ,293 acosts are expressed in Canadian dollars (CDN $1.00 = U.S. $0.73 at 1996 exchange rates). LOS, length of stay; ADR, adverse drug reaction; AED, antiepileptic drug. to calculate the nursing costs for patients experiencing an ADR during their stay by relating the length of the ADR episode to the overall length of stay may overestimate the actual costs. To precisely evaluate additional direct costs for an AED-induced ADR occurring during hospitalization, comparison with a sex-, age-, and diseasematched control group with no evidence of either an adverse drug event or a nosocomialinfection during hospitalization would have been informative, but this was not feasible. In the study by Evans et al. (19), it was estimated that patients who experienced an ADR during hospitalization had their stay increased by 1.94 days compared to control patients, and ADRs accounted for additional costs of U.S. $1,939 in affected patients. Similar results were found by Classen and colleagues (20), in which the mean attributable excess hospital costs were found to be U.S. $2,013 with an excess length of stay of 1.74 days. For a subset of cases with severe ADRs, the TABLE 3. Breakdown of costs for 13 patients with AED-induced ADRs leading to hospitalization or prolonged hospital stay ADR leading to ADR during hospitalization hospitalization All ADRs Type of costa (n = 8) (n = 5) (n = 13) Nursing, bed charges, overheads Mean f SD 3,064 f 3,127 4, ,085 3, ,066 Median 1,953 3,393 2,733 % total costs Physicians Mean & SD 486 f f f 302 Median % total costs Lab test Mean f SD 1,149* 1, i Median % total costs Noninvasive procedures Mean f SD 37 * f *59 Median % total costs Invasive procedures Mean f SD 11 f30 17 i f 32 Median % total costs Pharmacy Mean f SD 807 f 1, f 1,105 Median % total costs a Costs are expressed in Canadian dollars (CDN $1.00 = U.S. $0.73 at 1996 exchange rates). AED, antiepileptic drug; ADR, adverse drug reaction. Epilepsia, Vol. 39, Suppl. 7, 1998
5 COSTS OF ADVERSE REACTIONS TO AEDS S3 1 attributable length of stay was 3.6 days and the costs of hospitalization averaged U.S. $3,634. This cost of severe ADRs is close to the findings of our study, although we focused only on severe reactions to AEDs. In the same study by Classen and colleagues (20), the excess costs associated with each individual type of ADR, based on the major symptoms, were evaluated. For example fever, itching, or rash-symptoms we frequently observed in our patients with AED-induced reactions-were associated with estimated additional costs of U.S. $9,022, U.S. $677, and U.S. $1,868, respectively. The attributable length of stay for these reactions was 5.5, 0.7, and 1.4 days, respectively (20). Although severe cutaneous or hypersensitivity reactions associated with AEDs are rare and the individual costs associated with such reactions, as found in our study, are far from negligible, the impact on the overall therapy costs (including costs associated with ADRs) for patients receiving long-term AED treatment are probably minor. On the other hand, in 31% of our patients the AED therapy was used as a short-term prophylaxis after neurosurgery or cranial radiation. In this subgroup of patients, the high costs associated with severe AEDinduced ADRs may indeed have a major effect on the overall therapy costs. Severe reactions to AEDs are rare. In general, however, ADRs during AED therapy are not uncommon. In addition to potentially increasing the morbidity and therefore also influencing the quality of life, minor or moderate reactions also may give rise to additional costs (e.g., costs for diagnosis of the adverse event, additional drug therapy, therapeutic drug monitoring after switching to another AED), and hence would have an impact on the overall therapy costs. The finding that the ADRs analyzed in our study were, without exception, associated with older AEDs probably reflects the fact that some of the newer drugs were not marketed throughout our study period, and therefore their usage frequency was low compared to that of older AEDs. With the increasing use of newer drugs, the ADR pattern found in our study would probably change. LTG, for example, is associated with the AHS and with severe cutaneous adverse reactions (21-25). However, as yet there are no data regarding costs associated with such reactions for this newer AED. As suggested in a recent editorial by Dukes (26), any monetary measure of the adverse effects of drugs is to some extent artificial and incomplete. Our study has some limitations as well. The economic techniques used to identify the overall costs of illness involve determining the direct and indirect costs borne by the community. The direct costs of ADRs consist of the cost of treatment, hospitalization, avoidance (i.e., action taken to prevent ADRs), and detection (i.e., action taken to diagnose ADRs). Avoidance of costs is often omitted from calcu- lations because such costs are likely to be small in proportion to the other items (1). Because there is no general therapy to counteract and avoid some potential AEDinduced ADRs (in contrast to potassium supplements for patients being treated with thiazide diuretics or hematologic growth factors to prevent chemotherapy-induced neutropenia), costs for avoidance of ADRs were not included in our evaluation. The ADR-related costs we found in this study are specific to our institution, and therefore extrapolation of the results to other settings may be inaccurate. Our results nevertheless give an estimate of the type of resources consumed and the magnitude of the direct medical costs associated with the types of reactions analyzed in our study. We included only costs for patients hospitalized because of a severe cutaneous or hypersensitivity ADR or who experienced such an ADR during their hospital stay at our institution. We did not include the costs of the referring physician and preliminary evaluation because of the difficulty of obtaining such data in a retrospective review. Because serious hypersensitivity or cutaneous ADRs usually result in hospitalization, we believe that the contribution of such outpatient physician visits to the costs of serious reactions would be only minimal. Furthermore, we calculated only the direct costs and did not include indirect costs, such as the days lost from work and the implied temporary or permanent loss of productivity or the loss of the salaries of affected patients. These components would have greatly increased the cost impact. In conclusion, our study shows that the management of serious cutaneous or hypersensitivity ADRs to AEDs is related to considerable direct medical costs. These figures should be considered, along with the costs associated with drug acquisition, delivery, and treatment of all clinical successes and failures, in the overall assessment of the economic impact of a pharmacotherapy. Prospective collection of ADR-associated direct costs in clinical trials would be of value. Acknowledgments: This study was supported in part by Ciba-Geigy Canada, Ltd. Raymond G. Schlienger was supported by a grant from the Swiss National Science Foundation. Presented in part at the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, March 5, 1997, San Diego, CA. REFERENCES 1. Mach E, Venulet J. The economics of adverse reactions to drugs. WHO Chronicle 1975;29: Brodie M, Dichter M. Antiepileptic drugs. N Engl J Med 1996; 334: Keck P, McElroy S, Nemeroff C. Anticonvulsants in the treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci 1992;4: Pope H, McElroy S, Keck P, Hudson J. Valproate in psychiatric disorders: literature review and clinical guidelines. J Clin Psychiatry ;48:62-8.
6 S32 R. G. SCHLIENGER ET AL. 5. Chang D, Shear N. Cutaneous reactions to anticonvulsants. Semin Neurol 1992;12: Collaborative Group for Epidemiology of Epilepsy. Adverse reactions to antiepileptic drugs: a multicentre survey of clinical practice. Epilepsia 1986;27: Cloyd J, Brundage R. Valproic acid. In: Taylor W, Diers Caviness M, eds. A textbook for the clinical application of therapeutic drug monitoring. Irving, TX: Abbott Laboratories, Diagnostic Division, 1986: Mattson R, Cramer J. Phenobarbital toxicity. In: Woodbury DM, Pippenger CE, eds. Antiepileptic drugs. New York: Raven Press, 1982: Silverman A, Fairley J, Wong R. Cutaneous and immunologic reactions to phenytoin. J Am Acad Dermatol 1988;18: Pellock JM. Carbamazepine side effects in children and adults. Epilepsia 1987;28( Suppl 3):S Shear N, Spielberg S. Anticonvulsant hypersensitivity syndrome. J Clin Invest 1988;82: Tennis P, Stem RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997;49: Grant S, Heel R. Vigabatrin. Drugs 1991;41: Dichter M, Brodie M. New antiepileptic drugs. N Engl J Med 1996;334: Hughes D, Cockerell 0. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy. Seizure 1996;5: PMIC. International Classification of Diseases. 9th rev. Clinical Modification. 4th ed. Los Angeles: Practice Management Information Corp., Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30: Schneider P, Gift M, Rothermich E, Sill B. Cost of medicationrelated problems at a university hospital. Am J Heatrh System Pharm 1995;52: Evans R, Classen D, Stevens L, et al. Using a hospital system to assess the effects of adverse drug events. Proc Annu Symp Comput Appl Med Care 1993;17: Classen D, Pestotnik S, Evans R, Lloyd J, Bruke J. Adverse drug events in hospitalized patients. JAMA 1997;277: Campistol J, Geli M, Llistosella E, Molins J, Llobet M. Sindrome de Stevens-Johnson tras la introduccion de lamotrigina. Rev Neurol 1995;23: Jones D, Chhiap V, Resor S, Appel G, Grossman ME. Phenytoinlike hypersensitivity associated with lamotrigine. J Am Acad Dermatol 1997;36: Nicholson RJ, Kelly KP, Grant IS. Leucopenia associated with lamotrigine. BMJ I995;3 10: Sullivan JR, Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Ausrralas J Dermatol 1996;37: Sachs E, Ronnau AC, von Schmiedeberg S, Ruzicka T, Gleichmann E, Schuppe H-C. Lamotrigine-induced Stevens-Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro. Dermatology 1997;195: Dukes M. Economic costs of adverse drug reactions. Pharmucoeconomics 1992; 1 : Epilepsia, Vol. 39, Suppl. 7, 1998
Lam0 trig he-induced Severe Cutaneous Adverse Reactions
Epilepsia, 39(Suppl. 7):S22-S26, 1998 Lippincott Williams & Wilkins, Philadelphia 0 International League Against Epilepsy Lam0 trig he-induced Severe Cutaneous Adverse Reactions *Raymond G. Schlienger,
More informationPHENYTION, CARBAMAZEPINE, SODIUM VALPROATE AND LAMOTRIGINE INDUCED CUTANEOUS REACTIONS
PHENYTION, CARBAMAZEPINE, SODIUM VALPROATE AND LAMOTRIGINE INDUCED CUTANEOUS REACTIONS M. Ghaffarpour *, S. S. Hejazie, M. H. Harirchian and H. Pourmahmoodian Department of Neurology, Imam Khomeini Hospital,
More informationSuccessful re-introduction of lamotrigine after initial rash
Seizure 2000; 9: 282 286 doi: 10.1053/seiz.2000.0394, available online at http://www.idealibrary.com on Successful re-introduction of lamotrigine after initial rash F. M. C. BESAG, G. Y. T. NG & F. POOL
More informationDisclosure. Learning Objectives
Linda D. Leary, M.D. Associate Clinical Professor of Pediatrics & Neurology South Texas Comprehensive Epilepsy Center UT Health Science Center San Antonio Disclosure Linda D. Leary, M.D. discloses the
More informationRefractory epilepsy: treatment with new antiepileptic drugs
Seizure 2000; 9: 51 57 doi: 10.1053/seiz.1999.0348, available online at http://www.idealibrary.com on Refractory epilepsy: treatment with new antiepileptic drugs P. K. DATTA & P. M. CRAWFORD Department
More informationFDA Approves Carnexiv (carbamazepine) injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types
FOR IMMEDIATE RELEASE FDA Approves Carnexiv (carbamazepine) injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types Carnexiv is the first FDA-approved intravenous carbamazepine
More informationKeywords: treatment; epilepsy; population based cohort Institute of Neurology, University College London, London WC1N 3BG, UK
632 Institute of Neurology, University College London, London WC1N 3BG, UK S D Lhatoo JWASSander S D Shorvon Correspondence to: Professor J W Sander, Department of Clinical and Experimental Epilepsy, Institute
More informationDifficult to treat childhood epilepsy: Lessons from clinical case scenario
Difficult to treat childhood epilepsy: Lessons from clinical case scenario Surachai Likasitwattanakul, M.D. Department of Pediatrics Faculty of Medicine, Siriraj Hospital Natural history of Epilepsy Untreated
More informationTherapeutic strategies in the choice of antiepileptic drugs
Acta neurol. belg., 2002, 102, 6-10 Original articles Therapeutic strategies in the choice of antiepileptic drugs V. DE BORCHGRAVE, V. DELVAUX, M. DE TOURCHANINOFF, J.M. DUBRU, S. GHARIANI, Th. GRISAR,
More informationReview of Anticonvulsant Medications: Traditional and Alternative Uses. Andrea Michel, PharmD, CACP
Review of Anticonvulsant Medications: Traditional and Alternative Uses Andrea Michel, PharmD, CACP Objectives Review epidemiology of epilepsy Classify types of seizures Discuss non-pharmacologic and pharmacologic
More informationHealth economics and drug safety
Health economics and drug safety Professor Dyfrig Hughes FFRPS FBPhS FLSW Centre for Health Economics & Medicines Evaluation Bangor University, Wales @HughesDyfrig ADEs that are not reactions to a medicine
More informationAnticonvulsants Antiseizure
Anticonvulsants Antiseizure Seizure disorders Head trauma Stroke Drugs (overdose, withdrawal) Brain tumor Encephalitis/ Meningitis High fever Hypoglycemia Hypocalcemia Hypoxia genetic factors Epileptic
More informationNeuromuscular Disease(2) Epilepsy. Department of Pediatrics Soochow University Affiliated Children s Hospital
Neuromuscular Disease(2) Epilepsy Department of Pediatrics Soochow University Affiliated Children s Hospital Seizures (p130) Main contents: 1) Emphasize the clinical features of epileptic seizure and epilepsy.
More informationMonitoring and Antiepileptic Drug Safety
Practice Monitoring and Antiepileptic Drug Safety L. James Willmore, MD, FAAN, FANA ABSTRACT Treatment of patients with epilepsy strives for complete seizure control without intolerable drug side effects.
More informationTitle: Cutaneous Adverse Drug Reactions in Indian population: A systematic review
Title: Cutaneous Adverse Drug Reactions in Indian population: A systematic review Review question(s) To carry out a systematic review of the published evidence of the cutaneous adverse drug reactions in
More informationEpilepsy management What, when and how?
Epilepsy management What, when and how? J Helen Cross UCL-Institute of Child Health, Great Ormond Street Hospital for Children, London, & National Centre for Young People with Epilepsy, Lingfield, UK What
More informationRECENT MAJOR CHANGES Warnings and Precautions, Hemophagocytic
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMICTAL safely and effectively. See full prescribing information for LAMICTAL. LAMICTAL (lamotrigine)
More informationAdjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options
Seizure 1995: 4:37-44 Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options B.A. O'NEILL, M.R. TRIMBLE* & D.S. BLOOM Arthur D. Little Ltd, Berkley Square House,
More informationDOSAGE FORMS AND STRENGTHS Tablets: 25 mg, 100 mg, 150 mg, and 200 mg; scored. (3.1, 16)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
More informationMedications for Epilepsy What I Need to Know
Medications for Epilepsy What I Need to Know Safiya Ladak, BSc.Phm. Toronto Western Hospital, UHN Clinical Pharmacist, Neurology and Neurosurgery June 4, 2016 Learning Objectives Treatment options for
More informationSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: May 2009 LMT:2PI
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMICTAL safely and effectively. See full prescribing information for LAMICTAL. LAMICTAL (lamotrigine)
More informationSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 11/2011
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMICTAL safely and effectively. See full prescribing information for LAMICTAL. LAMICTAL (lamotrigine)
More informationDisclosures. AED Options. Epilepsy Pharmacotherapy: Treatment Considerations with Older AEDs
Epilepsy Pharmacotherapy: Treatment Considerations with Older AEDs BARRY E. GIDAL, PHARMD PROFESSOR SCHOOL OF PHARMACY & DEPT. OF NEUROLOGY Disclosures Speaking honoraria: UCB, Eisai, Sunovion Consultant:
More informationAED Treatment Approaches. David Spencer, MD Director, OHSU Epilepsy Center Professor, Department of Neurology
AED Treatment Approaches David Spencer, MD Director, OHSU Epilepsy Center Professor, Department of Neurology Audience Response Keypads Please utilize the keypad at your table to answer questions throughout
More informationRisk of Aplastic Anemia in Patients Using Antiepileptic Drugs
Epilepsia, 47(7):1232 1236, 2006 Blackwell Publishing, Inc. C 2006 International League Against Epilepsy Brief Communications Risk of Aplastic Anemia in Patients Using Antiepileptic Drugs Kim B. Handoko,
More informationPEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 - REVIEW
PEER REVIEW HISTORY BMJ Paediatrics Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form and are provided with free text boxes to elaborate
More informationLevetiracetam in patients with generalised epilepsy and myoclonic seizures: An open label study
Seizure (2006) 15, 214 218 www.elsevier.com/locate/yseiz CASE REPORT Levetiracetam in patients with generalised epilepsy and myoclonic seizures: An open label study Angelo Labate a,b, Eleonora Colosimo
More informationDilantin (phenytoin) ROBERT A. SCHWARTZ
Dilantin (phenytoin) ROBERT A. SCHWARTZ Bailey & Galyen Attorney in Charge, Mass Tort Litigation Managing Attorney, Houston 18333 Egret Bay Blvd., Suite 120 Houston, Texas 77058 Toll Free: (866) 715-1529
More informationTRANSPARENCY COMMITTEE OPINION. 19 July 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 July 2006 Keppra 250 mg, film-coated tablets Box of 60 tablets (CIP code: 356 013-6) Keppra 500 mg, film-coated
More informationChildren Are Not Just Small Adults Choosing AEDs in Children
Children Are Not Just Small Adults Choosing AEDs in Children Natrujee Wiwattanadittakun, MD Neurology division, Department of Pediatrics, Chiang Mai University Hospital, Chiang Mai University 20 th July,
More informationChallenging epilepsy with antiepileptic pharmacotherapy in a tertiary teaching hospital in Sri Lanka
Original Article Challenging epilepsy with antiepileptic pharmacotherapy in a tertiary teaching hospital in Sri Lanka S. H. Kariyawasam, Namal Bandara,* A. Koralagama,** Sunethra Senanayake*** Dept. of
More information7/31/09. New AEDs. AEDs. Dr. Yotin Chinvarun M.D. Ph.D. Comprehensive Epilepsy and Sleep disorder Program PMK hospital. 1 st genera*on AEDs
Dr. Yotin Chinvarun M.D. Ph.D. Comprehensive Epilepsy and Sleep disorder Program PMK hospital New AEDs AEDs NEW OLD Pregabalin Pregabalin 1 st genera*on AEDs Phenytoin Carbamazepine Valproate Phenobarbital
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationUpdate in Clinical Guidelines in Epilepsy
Why We Need Clinical Guidelines? Clinician needs advice! Update in Clinical Guidelines in Epilepsy Charcrin Nabangchang, M.D. Phramongkutklao College of Medicine Tiamkao S, Neurology Asia2013 Why We Need
More informationFrom. The Department of Pediatrics Dr. Mehtas Hospital
From The Department of Pediatrics Dr. Mehtas Hospital Case history A 12 yr old girl : Fever 5 days Redness of eyes & erythematous rashes over the body for 2 days Past: Febrile fits at 9 mo. Of age Afebrile
More informationCost-effective analysis of dual therapy in epilepsy, a study from India
Neurology Asia 2011; 16(4) : 309 314 Cost-effective analysis of dual therapy in epilepsy, a study from India 1 Sarita Goyal MD (Pharmacology), 2 DC Dhasmana MD (Pharmacology), 3 Deepak Goel MD DM (Neurology),
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 05 May 2010 LAMICTAL 2 mg, dispersible / chewable tablet B/30 (CIP: 354 581-7) LAMICTAL 5 mg, dispersible / chewable
More informationEPILEPSY: SPECTRUM OF CHANGE WITH AGE. Gail D. Anderson, Ph.D.
EPILEPSY: SPECTRUM OF CHANGE WITH AGE Gail D. Anderson, Ph.D. Incidence: 0.5% - 1.0% of U.S. population Peak incidence of onset: first 2 years of life, ages 5-7 years, early puberty and elderly. 125,000
More informationEpilepsy 7/28/09! Definitions. Classification of epilepsy. Epidemiology of Seizures and Epilepsy. International classification of epilepsies
Definitions Epilepsy Dr.Yotin Chinvarun M.D., Ph.D. Seizure: the clinical manifestation of an abnormal and excessive excitation of a population of cortical neurons Epilepsy: a tendency toward recurrent
More informationTherapeutic drug monitoring in epilepsy treatment
Therapeutic drug monitoring in epilepsy treatment Published Jun 24, 1998 Version 1 Findings by SBU Alert Drug monitoring as a means to adapt the dosage of antiepileptic drugs to achieve a particular concentration
More informationLAMICTAL XR (lamotrigine) extended-release tablets, for oral use Initial U.S. Approval: 1994
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMICTAL XR safely and effectively. See full prescribing information for LAMICTAL XR. LAMICTAL XR
More informationEpilepsy T.I.A. Cataplexy. Nonepileptic seizure. syncope. Dystonia. Epilepsy & other attack disorders Overview
: Clinical presentation and management Markus Reuber Professor of Clinical Neurology Academic Neurology Unit University of Sheffield, Royal Hallamshire Hospital. Is it epilepsy? Overview Common attack
More informationNew antiepileptic drugs
Chapter 29 New antiepileptic drugs J.W. SANDER UCL Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, Queen Square, London, and Epilepsy Society, Chalfont
More informationPharmaco-epidemiological and pharmaco-economic analysis of antiepileptic drugs at a tertiary level health care centre - a crosssectional
Original article: Pharmaco-epidemiological and pharmaco-economic analysis of antiepileptic drugs at a tertiary level health care centre - a crosssectional prospective study Dr. Shraddha Tatkare 1 *, Dr.
More informationErnie Somerville Prince of Wales Hospital EPILEPSY
Ernie Somerville Prince of Wales Hospital EPILEPSY Overview Classification New and old anti-epileptic drugs (AEDs) Neuropsychiatric side-effects Limbic encephalitis Non-drug therapies Therapeutic wishlist
More informationORIGINAL CONTRIBUTION. Comparative Effectiveness of 10 Antiepileptic Drugs in Older Adults With Epilepsy
ORIGINAL CONTRIBUTION Comparative Effectiveness of 10 Antiepileptic Drugs in Older Adults With Epilepsy Hiba Arif, MD; Richard Buchsbaum; Joanna Pierro, BA; Michael Whalen, BA; Jessica Sims, MD; Stanley
More informationAdverse Drug Reactions (ADRs) Outline
Adverse Drug Reactions (ADRs) Outline 1. What are Adverse Drug Reactions (ADRs)? WHAT WHY HOW 2. How important are ADRs and are they preventable? 3. What are the classifications and mechanisms of ADRs?
More informationBuspirone Carbamazepine Diazepam Disulfiram Ethosuximide Flumazeil Gabapentin Lamotrigine
CNS Depressants Buspirone Carbamazepine Diazepam Disulfiram Ethosuximide Flumazeil Gabapentin Lamotrigine Lorazepam Phenobarbital Phenytoin Topiramate Valproate Zolpidem Busprione Antianxiety 5-HT1A partial
More informationMonotherapy and polytherapy in Paediatric seizures: A prospective, observational study in a tertiary care teaching hospital
Original Research Article Monotherapy and polytherapy in Paediatric seizures: A prospective, observational study in a tertiary care teaching hospital Henry Daniel Raj T 1, Sylvia A 2*, Chidambaranathan
More informationOXCARBAZEPINE-INDUCED STEVENS-JOHNSON SYNDROME: A CASE REPORT
OXCARBAZEPINE-INDUCED STEVENS-JOHNSON SYNDROME: A CASE REPORT Lung-Chang Lin, 1,2 Ping-Chin Lai, 3 Sheau-Fang Yang, 4 and Rei-Cheng Yang 1,5 Departments of 1 Pediatrics and 4 Pathology, Kaohsiung Medical
More informationSeizures and you. Michael B. Lloyd, MD
Seizures and you Michael B. Lloyd, MD Objectives Definition Epidemiology Classification Epileptic syndromes Differential and recognition Work-up Treatment Frequently asked questions Definition Sudden
More informationDoes AED Prophylaxis Work in Posttraumatic Epilepsy December 2, 2012
Does AED Prophylaxis Work in Posttraumatic Epilepsy December 2, 2012 Marc A. Dichter, MD, PhD University of Pennsylvania American Epilepsy Society Annual Meeting Disclosure Name of Commercial Interest
More informationNew Medicines Profile
New Medicines Profile February 2010 Issue No. 10/02 Eslicarbazepine Concise evaluated information to support the managed entry of new medicines in the NHS Brand Name, (Manufacturer): Zebinix (Eisai Limited)
More informationNew AEDs in Uncontrolled seizures
New AEDs in Uncontrolled seizures Uncontrolled seizures/epilepsy Intractable epilepsy, Refractory epilepsy, Pharmacoresistant epilepsy Dr. Suthida Yenjun Traditionally, referred to therapeutic failure
More informationMONOTHERAPY IS PREferred
Monotherapy in Epilepsy Role of the Newer Antiepileptic Drugs Blanca Vazquez, MD NEUROLOGICAL REVIEW Background: Monotherapy is the goal for pharmacological treatment of epilepsy. Well-controlled trials
More informationlevetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd
Scottish Medicines Consortium Resubmission levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd 11 January 2008 The Scottish Medicines
More informationSlide 1. Slide 2. Slide 3. Objectives. Why should we care about the elderly? Antiseizure Drugs in Elderly Patients
Slide 1 Antiseizure Drugs in Elderly Patients Angela Birnbaum, Ph.D. Professor Epilepsy Research and Education Program Center for Clinical and Cognitive Neuropharmacology College of Pharmacy University
More informationRisk of Stevens Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics
Risk of Stevens Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics Maja Mockenhaupt, MD; John Messenheimer, MD; Pat Tennis, PhD; and Juergen Schlingmann Abstract Background:
More informationEpilepsy and EEG in Clinical Practice
Mayo School of Professional Development Epilepsy and EEG in Clinical Practice November 10-12, 2016 Hard Rock Hotel at Universal Orlando Orlando, FL Course Directors Jeffrey Britton, MD and William Tatum,
More informationUnit VIII Problem 7 Pharmacology: Principles of Management of Seizure Disorders
Unit VIII Problem 7 Pharmacology: Principles of Management of Seizure Disorders - Terminologies: Anti-convulsants: they are used to control convulsions seen in certain types of epilepsy. Convulsions may
More information8/30/10. How to use Antiepileptic drugs properly. 3nd generation AEDs. Introduction. Introduction. Introduction. AEDs. Dr.Yotin Chinvarun M.D., Ph.D.
Introduction How to use Antiepileptic drugs properly Modern treatment of seizures started in 1850 with the introduction of bromides, based on the theory that epilepsy was caused by an excessive sex drive
More informationAntiepileptics. Medications Comment Quantity Limit Carbamazepine. May be subject Preferred to quantity limit Epitol
Market DC Antiepileptics Override(s) Approval Duration Prior Authorization 1 year Step Therapy Quantity Limit *Indiana Medicaid See State Specific Mandate below *Maryland Medicaid See State Specific Mandate
More informationLAMICTAL GlaxoSmithKline
LAMICTAL GlaxoSmithKline Lamotrigine QUALITATIVE AND QUANTITATIVE COMPOSITION Tablets: LAMICTAL, 25, 50, 100 and 200 mg. Dispersible/Chewable Tablets: LAMICTAL, 2, 5, 25, 50, 100 and 200 mg. PHARMACEUTICAL
More informationCosting statement. Implementing NICE guidance. January NICE clinical guideline 137
The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care (partial update of NICE clinical guideline 20) Costing statement Implementing NICE guidance
More informationBIBLIOGRAPHIC REFERENCE TABLE FOR SODIUM VALPROATE IN CHILDHOOD EPILEPSY
BIBLIOGRAPHIC REFERENCE TABLE FOR SODIUM VALPROATE IN CHILDHOOD EPILEPSY Bibliographic Marson AG et al. for (Review). The Cochrane 2000 De Silva M et al. Romised or for childhood. Lancet, 1996; 347: 709-713
More informationEfficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities
Seizure 004; : 68 75 doi:0.06/s059-(0)0054-7 Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities B. HUBER, W. BÖMMEL, I. HAUSER, V. HORSTMANN,
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Drug Allergy. These podcasts are designed to give medical students an overview of key topics in pediatrics. The audio
More informationPatients with generalised epilepsy have a higher white blood cell count than patients with focal epilepsy
Original article Epileptic Disord 2012; 14 (1): 57-63 Patients with generalised epilepsy have a higher white blood cell count than patients with focal epilepsy Rani A Sarkis 1, Lara Jehi 1, Diosely Silveira
More informationIntervention [5] Comparison [6]
Cowan LD. The epidemiology of the epilepsies in children. Mental Retardation and Developmental Disabilities Res Reviews, 2002; 8: 171-181 Review article Paediatric patients Discusses incidence and prevalence
More informationPhenytoin versus Levetiracetam for Prevention of Early Posttraumatic Seizures: A Prospective Comparative Study
136 Original Article Phenytoin versus Levetiracetam for Prevention of Early Posttraumatic Seizures: A Prospective Comparative Study Kairav S. Shah 1 Jayun Shah 1 Ponraj K. Sundaram 1 1 Department of Neurosurgery,
More informationReview of health related quality of life evidence in the TLoC population
Appendix H Review of health related quality of life evidence in the TLoC population The aim of this review is to summarise the available evidence on healthrelated quality of life (HRQoL) that could be
More informationFINAL REPORT TO THE FLORIDA AGENCY FOR HEALTH CARE ADMINISTRATION (AHCA) Project 19
1 FINAL REPORT TO THE FLORIDA AGENCY FOR HEALTH CARE ADMINISTRATION (AHCA) Project 19 Prescription Utilization Patterns and Hospitalizations in Epilepsy Patients on Anti Epileptic Drugs Abraham G. Hartzema,
More informationEvidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy
Seizure (2006) 15, 112 116 www.elsevier.com/locate/yseiz Evidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy Luigi M. Specchio a,e, *, Giovanni Boero b,e,
More informationPROPHYLACTIC ANTICONVULSANT THERAPY
PROPHYLACTIC ANTICONVULSANT THERAPY Dr. Khalid Siddiqui FRCSC, ABNS, FAANS Consultant Neurosurgery Assistant Medical Director Dr Sulaiman Alhabib Medical Group, Al-Rayan PAPNS 2015 11/24/2015 1 Introduction
More informationTo Study The Adverse Effect of Carbamazepine in A Tertiary Care Teaching Hospital of North East India.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 5 Ver. VIII (May. 2017), PP 26-31 www.iosrjournals.org To Study The Adverse Effect of Carbamazepine
More informationEpilepsy in a children's hospital: an out-patient survey
Seizure 1995; 4:279-285 Epilepsy in a children's hospital: an out-patient survey A.P. HUGHES & R.E. APPLETON Roald Dahl E.E.G. Unit, Royal Liverpool Children's NHS Trust Address for correspondence: Dr
More informationRisk of seizure recurrence after antiepileptic drug withdrawal, an Indian study
Neurology Asia 2006; 11 : 19 23 Risk of seizure recurrence after antiepileptic drug withdrawal, an Indian study Archana VERMA DM (Neurology) MD, Surendra MISRA DM (Neurology) FRCP (Edin) Department of
More informationSODIUM CHANNEL BLOCKERS IN THE 21 ST CENTURY. Professor Martin J Brodie University of Glasgow Glasgow, Scotland
IN THE 21 ST CENTURY Professor Martin J Brodie University of Glasgow Glasgow, Scotland Eisai SODIUM CHANNEL BLOCKERS Declaration of interests UCB Pharma GlaxoSmithKline Lundbeck Takeda Advisory board,
More informationFemale patients or caregivers counseled* at least once a year about how epilepsy and its treatment may affect contraception OR pregnancy.
MEASURE #6: Counseling for Women of Childbearing Potential with Epilepsy Measure Description All female patients of childbearing potential (12-44 years old) diagnosed with who were counseled or referred
More informationPregnancy and Epilepsy
Pregnancy and Epilepsy Nowhere is the problem more evident or more complicated than in pregnancy. In the United States, epilepsy affects nearly one million women of childbearing potential. Alarm bells
More informationI. Introduction Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs)
1 2 I. Introduction Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs) are those which decrease the frequency and/or severity
More informationORIGINAL CONTRIBUTION. patients. According to
Hospital-Onset Seizures An Inpatient Study ORIGINAL CONTRIBUTION Madeline C. Fields, MD; Daniel L. Labovitz, MD; Jacqueline A. French, MD Objectives: To describe demographic and clinical characteristics
More informationSEIZURES PHARMACOLOGY. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
SEIZURES PHARMACOLOGY University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Understand the pharmacodynamics involved in the medications used to treat seizures
More informationTegretol and low sodium levels
Tegretol and low sodium levels Gogamz Menu 7-2-2018 Easy to read patient leaflet for Tegretol. If you have taken certain drugs used for low mood. Signs of low sodium levels like headache,. Trigeminal Neuralgia
More information2018 American Academy of Neurology
Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-Onset Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of
More informationIND Exemption: Case Scenarios. Scenario No. 1
IND Exemption: Case Scenarios Scenario No. 1 Investigator plans to study anti-flu drug to treat flu symptoms in children under the age of 10 Drug INFLUN is currently approved in the pediatric setting,
More informationWhen choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E.
... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs Based on a presentation by Barry E. Gidal, PharmD Presentation Summary A physician s choice of an antiepileptic drug (AED) usually depends
More informationPhenytoin, Levetiracetam, and Pregabalin in the Acute Management of Refractory Status Epilepticus in Patients with Brain Tumors
Neurocrit Care (2012) 16:109 113 DOI 10.1007/s12028-011-9626-4 ORIGINAL ARTICLE Phenytoin, Levetiracetam, and Pregabalin in the Acute Management of Refractory Status Epilepticus in Patients with Brain
More informationZonisamide for migraine prophylaxis in refractory patients
Thomas Jefferson University Jefferson Digital Commons Department of Neurology Faculty Papers Department of Neurology March 2006 Zonisamide for migraine prophylaxis in refractory patients Avi Ashkenazi
More informationAN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON SECOND GENERATION TREATMENT OPTIONS
Volume 24, Issue 1 October 2008 AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON SECOND GENERATION TREATMENT OPTIONS Jason Richey, Pharm.D. Candidate Epilepsy is a neurological disorder characterized by sudden
More informationimproving the patient s quality of life.
Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs) are those which decrease the frequency and/or severity of seizures in
More informationOriginal Article. Emergency Department Evaluation of Ventricular Shunt Malfunction. Is the Shunt Series Really Necessary? Raymond Pitetti, MD, MPH
Original Article Emergency Department Evaluation of Ventricular Shunt Malfunction Is the Shunt Series Really Necessary? Raymond Pitetti, MD, MPH Objective: The malfunction of a ventricular shunt is one
More informationPrevalence and pattern of adverse cutaneous drug reactions presenting to a tertiary care hospital
International Journal of Research in Dermatology Janardhan B et al. Int J Res Dermatol. 2017 Mar;3(1):74-78 http://www.ijord.com Original Research Article DOI: http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20164248
More informationPrescribing and Monitoring Anti-Epileptic Drugs
Prescribing and Monitoring Anti-Epileptic Drugs Mark Granner, MD Clinical Professor and Vice Chair for Clinical Programs Director, Iowa Comprehensive Epilepsy Program Department of Neurology University
More informationPrescribing for substance misuse: alcohol detoxification. Clinical background
Prescribing for substance misuse: alcohol detoxification POMH-UK Quality Improvement Programme. Topic 14a: baseline Clinical background 1 2014 The Royal College of Psychiatrists. For further information
More informationSEIZURE CONTROL * DAY & NIGHT
SEIZURE CONTROL * DAY & NIGHT Equetro (carbamazepine) Extended-Release Capsules Approved for Use in Treating Epilepsy * *PLEASE SEE FOLLOWING PAGES FOR SPECIFIC INDICATIONS. PLEASE SEE IMPORTANT SAFETY
More informationDisclosures. Objectives 2/16/2015. Women with Epilepsy: Seizures in Pregnancy and Maternal/Fetal Outcomes
Women with Epilepsy: Seizures in Pregnancy and Maternal/Fetal Outcomes 40 th Annual Progress in OBGYN February 19, 2015 Jennifer L. DeWolfe, DO Associate Professor UAB Epilepsy Center Director, BVAMC Sleep
More informationPaediatric Epilepsy Update N o r e e n Te a h a n canp C o l e t t e H u r l e y C N S E p i l e p s y
Paediatric Epilepsy Update 2018 N o r e e n Te a h a n canp C o l e t t e H u r l e y C N S E p i l e p s y Epilepsy Service CUH ~550 children New diagnosis-education, support, clinic follow up Epilepsy
More informationSKIN REACTIONS WITH PSYCHOTROPICS: A SYSTEMATIC REVIEW
SKIN REACTIONS WITH PSYCHOTROPICS: A SYSTEMATIC REVIEW *Anderson Isaac, PharmD Candidate, 2019 Pooja Patel, PharmD Candidate, 2019 Katelyn Thomasson, PharmD Candidate, 2019 Erika Tillery, PharmD, BCPP,
More informationTIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain
TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain Second Low-Dose SoluMatrix NSAID from Iroko Now Available by Prescription PHILADELPHIA, June 29, 2015 Iroko Pharmaceuticals, LLC,
More information